Tiffany McCormack
Reno, NVNPI 1083789481
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. AbbVie accounts for 88.4% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2021 at $8,108 and has fallen 79.4% since, to $1,673 in 2025.
Across 206 payments — averaging $126.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$23K
- Merz North America, Inc.$917
- Endo Pharmaceuticals Inc.$817
- Galderma Laboratories, L.p.$793
- Mentor Worldwide LLC$243
- Revance Therapeutics, Inc.$156
- plus $107 from 3 others
Across 1 payment — averaging $21,792 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Davol Inc.$22K
What the payments were for
- Consulting fees$10,47740%
- Speaking & faculty fees$11,05242%
- Food & beverage$4,51617%
- Education$490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 129 | $23,060 |
| Merz North America, Inc. | 6 | $917 |
| Endo Pharmaceuticals Inc. | 2 | $817 |
| Galderma Laboratories, L.p. | 55 | $793 |
| Mentor Worldwide LLC | 9 | $243 |
| Revance Therapeutics, Inc. | 2 | $156 |
| Motiva USA, LLC | 1 | $69 |
| Sientra, Inc. | 1 | $26 |
| Apyx Medical Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 42 | $323 |
| Cephalexin | 60 | $297 |
| Ondansetron OdtOndansetron | 30 | $168 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 37 | $115 |
| Cyclobenzaprine Hcl | 12 | $49 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.